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Our aim was to improve the prediction of unfavorable histopathology (UH) in neuroblastic
tumors through combined imaging and biochemical parameters.
Methods
123I-MIBG SPECT and MRI was performed before surgical resection or biopsy in 47 conse-
cutive pediatric patients with neuroblastic tumor. Semi-quantitative tumor-to-liver count-rate
ratio (TLCRR), MRI tumor size and margins, urine catecholamine and NSE blood levels of
neuron specific enolase (NSE) were recorded. Accuracy of single and combined variables
for prediction of UH was tested by ROC analysis with Bonferroni correction.
Results
34 of 47 patients had UH based on the International Neuroblastoma Pathology Classifica-
tion (INPC). TLCRR and serum NSE both predicted UH with moderate accuracy. Optimal
cut-off for TLCRR was 2.0, resulting in 68% sensitivity and 100% specificity (AUC-ROC
0.86, p < 0.001). Optimal cut-off for NSE was 25.8 ng/ml, resulting in 74% sensitivity and
85% specificity (AUC-ROC 0.81, p = 0.001). Combination of TLCRR/NSE criteria reduced
false negative findings from 11/9 to only five, with improved sensitivity and specificity of
85% (AUC-ROC 0.85, p < 0.001).
Conclusion
Strong 123I-MIBG uptake and high serum level of NSE were each predictive of UH. Com-
bined analysis of both parameters improved the prediction of UH in patients with neuroblas-
tic tumor. MRI parameters and urine catecholamine levels did not predict UH.
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Introduction
Based on the grade of Schwannian stromal development, neuroblastic tumors are divided into
three histopathologic categories: neuroblastoma, ganglioneuroblastoma and ganglioneuroma
[1]. Risk of progression and mortality in patients with neuroblastic tumors is critically deter-
mined by their histopathology, but also by tumor genetics and the extent of disease at primary
staging [2–3]. All three factors have been included in The International Neuroblastoma Risk
Group (INRG) Classification System [4]. Risk stratification according to INRG is critical for
therapeutic decision making, since patients with undifferentiated neuroblastoma require more
aggressive treatment than do patients with, for example, ganglioneuroma [5]. Risk stratification
of neuroblastic tumors is usually performed through histological examination of tumor speci-
mens after surgery. Pre-surgical and non-invasive risk estimation by imaging or serum tumor
markers may contribute important information with the potential to guide neo-adjuvant ther-
apy. Magnetic resonance imaging (MRI), scintigraphy using meta-[123I]-iodobenzylguanidine
(123I-MIBG), as well as blood and urine tests are routinely performed for pre-operative staging.
Each of these examinations determines a different risk factor for prediction of tumor aggres-
siveness: In particular, we have recently linked findings for semiquantitative 123I-MIBG uptake
on single-photon emission computed tomography (SPECT) to results from tumor histopathol-
ogy [6]. Here we made a semiquantitative assessment of 123I-MIBG uptake as the tumor-to-
liver ratio on SPECT images, an index which is less susceptible to misassignment of uptake
from overlying liver or intestines, as can occur in planar scintigraphy images. Results of other
trials over the past few decades have linked tumor marker concentrations in serum and urine
to histopathology and patient outcome [7–11]. In the case of MRI, image-defined risk factors
(IDRF) can indicate the probability of malignancy [12]. However, these three types of investi-
gations have limited diagnostic accuracy for prediction of tumor phenotype. We hypothesized
that a combined analysis of imaging and tumor marker characteristics might overcome this
limitation, so as to improve substantially the overall diagnostic accuracy for prediction of high-
risk histopathology in patients with neuroblastic tumor.
Materials and Methods
Patients
Patients were included retrospectively. Inclusion criteria were (a) histopathologically proven
neuroblastic tumor; (b) scintigraphy, MRI and urine/blood tests before surgery/biopsy; (c) a
maximum interval of 50 days between any diagnostic test (scintigraphy, MRI, or serum/urine
tests) and surgery/biopsy; and (d) no tumor-directed treatment between diagnostic tests and
surgery/biopsy. 47 consecutive pediatric patients with staging examinations between January
2006 and January 2012 met our criteria. The retrospective study protocol was approved by the
local ethics committee (Ethikkommission der Medizinischen Fakultät der LMUMünchen),
and written informed consent for entry into the study was waived. Written informed consent
(as outlined in PLOS consent form) was obtained from legal guardians of two individuals to
publish case details. Mean time interval between scintigraphy and MRI/tumor marker/surgery
or biopsy was 5/3/12 days (range: 0–50 days). Patients were staged according to the Interna-
tional Neuroblastoma Staging System (INSS) [2].
Serum NSE and urine catecholamines
24 hour urine samples were collected in a container prefilled with hydrochloric acid (10%).
Urine levels of creatinine, the catecholamines dopamine (DP), noradrenaline (NA), and adren-
aline (A) and their metabolites metanephrine (MN), vanillylmandelic acid (VMA), and
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homovanillic acid (HVA) were measured by high-performance liquid chromatography
(Chromsystems, Martinsried, Germany). Blood samples were drawn at the end of urine collec-
tion and serum levels of neuron-specific enolase (NSE) were determined by an automated
Elecsys 2010 System (Roche Diagnostics, Mannheim, Germany).
Imaging
Scintigraphy was performed under thyroid blockade with p.o. sodium perchlorate at a dose of
10 mg/kg/day over three days. The first sodium perchlorate dose was administered 30–60 min
before application of 123I-MIBG, which was administered i.v. at a dose adapted to body weight
according to specifications of the European Association of Nuclear Medicine (EANM) [13].
Images were acquired using a dual-head gamma camera Prism 2000 XP (Picker Inc, Cleveland,
OH, USA) starting 24h after tracer administration. Spot images of the whole body dorsal/ven-
tral view were obtained in a matrix of 256 x 256 pixels with a maximum acquisition time of ten
minutes per image. SPECT images of the tumor-affected regions were acquired in all cases at
approximately 24h after tracer administration (3° steps, 2 x 180°, 15 seconds per step). Iterative
reconstruction of the SPECT was based on an OSEM algorithm (3 iterations, 15 subsets, 128 x
128 matrix).
MRI was performed on a 1.5 T scanner (Magnetom Vision, Siemens, Erlangen, Germany).
The field-of-view encompassed the region suspected for tumor involvement. Axial, coronal, or
sagittal short tau inversion recovery (STIR) images and spin echo or fast spin echo T2-weighted
and T1-weighted images with and without administration of gadopentetate dimeglumine
(Magnevist, Schering, Berlin, Germany; 0.2 ml/kg of body weight) were obtained. To avoid
motion artifacts, light sedation was necessary in four of the 47 patients. Legal guardians of all
patients gave standard written consent to undergo scintigraphy and MRI.
Image analysis
Images were reviewed on a HERMES workstation (Nuclear Diagnostics, Haegersten, Sweden).
Tumor lesions were identified on MRI images at the primary site as any mass adjacent to the
adrenal glands, in a paravertebral location, or in other tumor-typical regions of the head, tho-
rax, abdomen or pelvis. Margins of the mass were judged as either (a) well-defined, referring to
a well circumscribed lesion or (b) ill-defined, referring to an irregularly shaped lesion with infil-
tration or encasement of adjacent structures. Images were fused using the HERMES software
algorithm. Side-by-side and fused MRI images were used to localize lesions on SPECT. Largest
MRI diameter and the tumor-to-liver count-rate ratio (TLCRR) on 123I-MIBG SPECT were
determined for all patients, who had in part been reported in our previous study [6]. We modi-
fied our TLCRR metric in order to minimize the effects of signal noise and tissue inhomogene-
ity, but following closely in our new criteria the PERCIST 1.0 definition for tumor and liver
uptake [14]: Peak tumor count rate was defined as the average count rate in a 3 cm3 spherical
VOI around the voxel with highest count rate in the tumor, which gives a high tumor-related
tracer activity concentration without excessive statistical noise. We elected to use a volume
three times larger than the PERCIST definition to accommodate the lower resolution of
SPECT versus PET. In accordance with PERCIST, we defined liver background count rate as
the mean activity concentration in a 3 cm diameter spherical ROI placed in the central right
hepatic lobe or, in case of hepatic metastases, in other non-diseased areas of the liver. TLCRR
was defined as peak tumor count rate divided by the liver background. Image analyses were
performed by two experienced readers (W.F. and T.P.). MRI and scintigraphy were reviewed
separately by both readers with knowledge of clinical data, but without knowledge of the
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histopathological findings. In case of any disagreement, images were reviewed by both readers
together and consensus decision was made after discussion of the case.
Histopathology
Tumors were classified in accordance with the International Neuroblastoma Pathology Classi-
fication System (INPC) on the basis of the proportion of undifferentiated tumor cells into the
following groups [15]: (1) Ganglioneuroma (Schwannian stroma-dominant); Ganglioneuro-
blastoma, of which either (2) intermixed (Schwannian stroma-rich) or (3) nodular (Schwan-
nian stroma-rich/stroma dominant and stroma-poor); (4) Neuroblastoma (Schwannian
stroma-poor). Based on INPC criteria, assignment to groups 1 or 2 was judged favorable,
whereas groups 3 and 4 were judged as unfavorable [15]. Resected samples were examined sep-
arately at the Department of Pathology of the Ludwig-Maximilians-University of Munich, Ger-
many and at the German Pediatric Tumor Registry of the Department of Pediatric Pathology,
University of Kiel; the separate analysis did not in any individual patient result in discordant
findings.
Statistical analysis
Characteristics are presented as number (percent) or mean ± standard deviation (SD). Parame-
ters had been tested for normality using the Shapiro-Wilk test, which rejected the null-hypoth-
esis of normal distribution. Therefore, the Mann-Whitney test was used for unpaired
comparison between two subgroups. Area under the receiver-operating-characteristic
(AUC-ROC) curve, 95% confidence interval (CI) and corresponding p values were calculated
for prediction of UH. No more than ten variables were included, ensuring a minimum ratio of
about five individuals for every variable [16]. Significance was set at p< 0.005 in accordance
with Bonferroni correction for multiple tests (p< 0.05 divided by ten, the number of vari-
ables). Optimal cut-off was defined as the point on the ROC curve which is farthest from the
line of equality (Youden index). A bar chart was drawn in ascending order for individual values
including the optimal cut-off value to illustrate the number of false positive and false negative
findings for each significant variable. Sensitivity (SE), specificity (SP), positive predictive value
(PPV), negative predictive value (NPV), accuracy (AC), and relative risk (RR) were calculated
for significant variables using the optimal cut-off as determined by ROC analysis. The SPSS
software package (version 15.0, SPSS, Inc., Chicago, Illinois, USA) was used for statistical
analyses.
Results
Characteristics of the study cohort
Patient characteristics are given in Table 1. Median age was two years and six months (range: 1
month– 19 years and 9 months). 31 of 47 (66%) primary tumors were neuroblastoma and 41
of 47 (87%) were located within the abdomen. 33 of 47 patients (70%) had INSS neuroblastoma
disease stage III and IV based on histopathology and imaging findings at diagnosis. Tumor
marker concentration in patients with favorable (FH) versus unfavorable histopathology (UH)
and corresponding p values are given in Table 2. According to the Mann-Whitney test with
correction for multiple comparisons only serum NSE was significantly elevated in the UH
group, whereas all other tumor markers showed no significant difference.
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ROC analysis of image parameters and tumor marker concentrations
A total of ten parameters were analyzed for their accuracy to predict UH. These were MRI size,
MRI margins, 123I-MIBG TLCRR, serum NSE, and urine concentration of three catechol-
amines and three catecholamine metabolites, normalized by 24 hour creatinine levels. Results
are given in Table 3. Type of MRI margins separated favorable and unfavorable histopathology
with an AUC-ROC of 0.68, although accuracy of prediction did not reach statistical signifi-
cance for this parameter. TLCRR, MN and serum NSE each had an AUC-ROC 0.70 with
p< 0.05. However, only TLCRR and serum NSE were considered significant after Bonferroni
correction for multiple tests (p< 0.005; AUC-ROC 0.80). The Youden index revealed an
optimal cut-off of 2.0 for TLCRR and 25.8 ng/ml for serum NSE. ROC curves and optimal cut-
off for prediction of UH are illustrated in Fig 1. Bar charts in ascending order are shown in Fig
2 separately for TLCRR and serum NSE. False positive/false negative results were seen in 0/11
cases for TLCRR and in 2/9 cases for serum NSE.
Diagnostic accuracy of separate versus combined TLCRR and NSE
analysis
Additional analysis was performed by combining both parameters with stand-alone significant
prediction according to ROC analysis: A positive result in either TLCRR or NSE was taken as a
Table 1. Patient characteristics. INSS = International Neuroblastoma Staging System.
Patient characteristic (n = 47) Absolute number (percent)
INPC group
Ganglioneuroma 9 (19)
Ganglioneuroblastoma intermixed 4 (9)










Table 2. Urine catecholaminemetabolite levels and serumNSE in patients with favorable histopathology (FH) and unfavorable histopathology
(UH) according to the International Neuroblastoma Pathology Classification (INPC). Concentrations are given as mean ± standard deviation (SD). Dif-
ference was tested by unpaired Mann-Whitney test including Bonferroni correction for multiple comparisons (p < 0.005*). MN = metanephrine,
VMA = vanillylmandelic acid, A = adrenaline, NA = noradrenaline, HVA = homovanillic acid, DP = dopamine, NSE = neuron-specific enolase.
Tumor marker (n = 47) FH UH p
MN (mg/g) 1.1 ± 1.1 3.3 ± 5.6 0.036
VMA (mg/g) 11.2 ± 6.5 54.4 ± 123.1 0.157
A (μg/g) 10.6 ± 8.9 12.8 ± 33.6 0.161
NA (μg/g) 69.1 ± 49.7 142.0 ± 335.9 0.686
HVA (mg/g) 15.1 ± 7.4 33.0 ± 43.4 0.433
DP (mg/g) 878.8 ± 576.8 1729.0 ± 3193.7 0.784
NSE (ng/ml) 23.0 ± 4.9 55.3 ± 74.0 0.001*
doi:10.1371/journal.pone.0132809.t002
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combined positive, whereas a negative result in TLCRR and NSE was taken as combined nega-
tive, given the high false negative rate for each single variable noted above. The diagnostic per-
formance of TLCRR, NSE and their combined analysis for prediction of UH is given in
Table 4. TLCRR and NSE were associated with equal relative risk of about two, but in the
Table 3. Results of the ROC analysis. Accuracy of several imaging parameters and tumor markers for prediction of unfavorable histopathology was tested
by ROC analysis using Bonferroni correction for multiple comparisons. Corresponding AUC-ROC, p value and 95%CI are given.
95% CI
Parameter (n = 47) AUC-ROC p upper limit lower limit
MRI size 0.40 0.279 0.24 0.56
MRI margins 0.68 0.053 0.51 0.86
TLCRR 0.86** < 0.001* 0.76 0.97
MN 0.70 0.036 0.53 0.87
VMA 0.63 0.157 0.48 0.79
A 0.37 0.161 0.19 0.55
NA 0.54 0.686 0.37 0.71
HVA 0.57 0.433 0.41 0.73
DP 0.47 0.784 0.31 0.64
NSE 0.81** 0.001* 0.68 0.93
**AUC-ROC > 0,80.
*p < 0.005 in accordance with Bonferroni correction.
ROC = receiver-operating-characteristic, AUC = area under the curve, CI = confidence interval, MRI = magnetic resonance imaging, TLCRR = tumor-to-
liver count-rate ratio, MN = metanephrine, VMA = vanillylmandelic acid, A = adrenaline, NA = noradrenaline, HVA = homovanillic acid, DP = dopamine,
NSE = neuron-specific enolase.
doi:10.1371/journal.pone.0132809.t003
Fig 1. ROC of TLCRR and serumNSE for prediction of unfavorable histopathology.Receiver-
operating-characteristic (ROC) is given for TLCRR (dashed line) and serum NSE (continuous line).
AUC-ROCwas 0.86 for TLCRR. Optimal cut-off determined by the Youden index was 2.0 (*), resulting
in a sensitivity of 68% and a specificity of 100%. AUC-ROCwas 0.81 for serum NSE. Optimal cut-off was
25.8 ng/ml (**) with a sensitivity of 74% and a specificity of 85%. AUC-ROC = area under the receiver-
operating-characteristic, TLCRR = tumor-to-liver count-rate ratio, NSE = neuron-specific enolase.
doi:10.1371/journal.pone.0132809.g001
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combined analysis there was a three-fold higher risk of UH in case of a combined positive
result as compared to a combined negative result. Combined analysis reduced the false negative
rate to five cases (as compared to 11/9 for stand-alone TLCRR/NSE), and furthermore gave the
Fig 2. Results for (A) TLCRR and (B) serumNSE with corresponding histopathology for each patient
(n = 47). Patients with unfavorable histopathology (UH) are shown with black bars, and patients with
favorable histopathology (FH) are shown with white bars, all of which are ordered in ascending magnitude.
Cut-off values determined by ROC analysis are indicated by horizontal lines. ROC = receiver-operating-
characteristic, TLCRR = tumor-to-liver count-rate ratio, NSE = neuron-specific enolase.
doi:10.1371/journal.pone.0132809.g002
Table 4. Performance of TLCRR, NSE and combined analysis for prediction of unfavorable histopathology. Sensitivity (SE), specificity (SP), positive
predictive value (PPV), negative predictive value (NPV), and accuracy (AC) are each given in percent using optimal cut-off as determined by ROC analysis.
Relative risk (RR) was calculated. TLCRR = tumor-to-liver count-rate ratio, NSE = neuron-specific enolase, ROC = receiver-operating-characteristic.
Parameter Cut-off SE SP PPV NPV AC RR
TLCRR 2.0 68 100 100 54 77 2.2
NSE 25.8 ng/ml 74 85 93 55 77 2.1
Combined - 85 85 94 69 85 3.0
doi:10.1371/journal.pone.0132809.t004
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highest value for summed sensitivity plus specificity and accuracy scores. Figs 3 and 4 show
two examples of true positive findings in the combined analysis.
Discussion
MRI, 123I-MIBG scintigraphy and tumor marker analysis are widely used in the initial and fol-
low-up assessment of patients with suspected neuroblastic tumor. All three modalities have
established criteria for evaluation of tumor agressiveness and the extent of disease: These crite-
ria include image-defined risk factors (IDRF) for the case of MRI, analysis of radiotracer uptake
and distribution for the case of scintigraphy, and cut-off levels for urine or serum tumor mark-
ers. The aim of this study was to combine modalities so as to provide improved prediction of
tumor histopathology as compared to the limited prediction from any single modality. We
therefore tested ten variables for their accuracy to predict INPC unfavorable histopathology
(UH), and combined the two individual parameters with good predictive value so as to obtain
optimal diagnostic performance. Bonferroni correction was included to reduce the probability
of false positive findings arsing from multiple testing.
Fig 3. True positive prediction of unfavorable histopathology (UH) by combined TLCRR/NSE criteria in a 14 year old boy. T1-weighted axial MRI with
(A) and without (C) contrast enhancement, 123I-MIBG SPECT (D) and fused SPECT/MRI (B) of the lower abdomen are shown. Tumor is depicted as contrast
enhancing lesion in a paravertebral location (A, arrow)with infiltration of the L5 neuroforamen (A, double arrow). Tumor-to-liver count-rate ratio (TLCRR)
was < 2.0 (D, false negative). Serum neuron-specific enolase (NSE) level was > 25.8 ng/ml (D, true positive). Combined analysis resulted in a true positive
finding for UH. Undifferentiated neuroblastoma was confirmed by histopathology following surgery.
doi:10.1371/journal.pone.0132809.g003
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The mean level of each tumor marker (MN, VMA, A, NA, HVA, DP, and NSE) was higher
in patients with UH as compared to the FH group, however only serum NSE showed a signifi-
cant correlation with histopathology in our analysis. Association between NSE level and INPC
group has not been analyzed previously. However several trials have shown a significant corre-
lation between serum NSE and patient prognosis. Lau et al. reported a high correlation between
serum NSE and overall survival for all tumor stages in a cohort of 128 patients with neuroblas-
tic tumor [17]. In their analysis, the risk for brief survival was increased by five-fold when the
NSE level exceeded 100 ng/ml, whereas urine catecholamine levels did not generally correlate
with survival [17]. Berthold et al. analyzed the prognostic value of different serum and urinary
tumor markers for relapse or progression prediction in a series of 196 patients with neuroblas-
toma [18]. In that study, serum NSE proved to be the best predictor for local or distant progres-
sion, whereas urinary VMA and HVA both had low sensitivity [18]. We likewise found no
significant correlation between urine catecholamine or catecholamine metabolite levels and
high-risk histopathology. The urine metanephrine level did have some correlation with
Fig 4. True positive prediction of unfavorable histopathology (UH) by combined TLCRR/NSE criteria in a 4 month old girl. T1-weighted axial MRI
with (A) and without (C) contrast enhancement, 123I-MIBG SPECT (D) and fused SPECT/MRI (B) of the abdomen are shown. Images show a lesion with
contrast enhancement (A, arrow) and infiltration of the L2 neuroforamen (A, double arrow). Tumor-to-liver count-rate ratio (TLCRR) was > 2.0 (D, true
positive). Serum neuron-specific enolase (NSE) level was < 25.8 ng/ml (D, false negative). Combined analysis resulted in a true positive finding for UH.
Poorly differentiated neuroblastoma was confirmed by histopathology following surgery.
doi:10.1371/journal.pone.0132809.g004
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unfavorable histopathology (AUC-ROC 0.70), however was not considered significant after
Bonferroni correction. Of course, our study is limited by its retrospective design and the low
number of patients, which was a consequence of our stringent inclusion criteria. Therefore our
multifactorial analysis did not have the statistical power necessary to detect a priori low corre-
lation between histopathology and tumor marker concentrations; this might be best achieved
in a prospective study with particular hypotheses based upon the present results.
The presence of infiltration or encasement of adjacent structures on MRI is considered a
key risk factor for malignancy of neuroblastic tumors [12]. Indeed, we found that detection of
ill-defined margins showed some correlation with UH, but this association did not reach statis-
tical significance. Likewise, MRI size was not specifically associated with UH, as 11/13 (85%) of
our patients with ganglioneuroma or intermixed ganglioneuroblastoma had lesions larger than
five cm in diameter. However, MRI presents its own advantages for the diagnosis of neuroblas-
toma, given its high sensitivity for detecting bone marrow infiltration, and its precise delinea-
tion of the extent of intraspinal tumors [19]. Therefore, we assert that 123I-MIBG scintigraphy
in conjunction with MRI give the optimal findings for risk stratification and surgery planning.
In a previous study Brans et al. categorized uptake of 123I-MIBG on planar images by using
a seven-point visual scale in 26 patients with neuroblastic tumor [20]. In their analysis no cor-
relation between 123I-MIBG uptake and histopathology was found, however a more accurate
semiquantitative analysis of tracer uptake instead of visual rating was suggested. As compared
to our previous study [6], we now implemented an improved version of our semiquantitative
tumor-to-liver uptake ratio determined on SPECT images and found a close association
between the intensity of 123I-MIBG uptake and histopathological subtype of neuroblastoma.
This result also concurs with findings of Okuyama et al., who applied a four-grade visual scale
for rating tracer uptake intensity in 23 neuroblastic tumor patients [21]. We now categorized
our neuroblastic tumors into favorable (FH) and unfavorable (UH) to comply with INPC prog-
nostic groups [1]. TLCRR had high specificity and a good AUC-ROC (0.86) based on the inter-
pretation guideline presented by Swets et al. [22], but with quite low sensitivity due to the high
rate of false negative findings for detection of UH (23%). The corresponding false negative rate
of serum NSE was lower than for TLCRR (9 versus 11), and there was overlap for false negative
results only in five patients. In our new combined analysis, a negative result had to have con-
cordant negative findings for both TLCRR and serum NSE. By using this algorithm, the rate of
false negative findings was reduced by approximately one half. In the combined analysis, the
overall sensitivity, accuracy and relative risk were thus substantially improved as compared to
each single parameter.
Conclusion
Strong 123I-MIBG uptake and high levels of serum NSE are predictive of unfavorable histopa-
thology in pediatric patients. Combined analysis of both parameters reduced false negative
findings and improved accuracy for prediction of unfavorable histopathology in patients with
neuroblastic tumor. If these findings should be confirmed in a larger group of patients, we
argue that a combination of both parameters might perform well for pre-surgical and non-
invasive prediction of patient risk. MRI parameters and urine catecholamine levels did not pre-
dict high-risk histopathology.
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